Asiatic Laboratories (DHA:ASIATICLAB) Debt-to-EBITDA : 0.00 (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ASIATICLAB Asiatic Laboratories Ltd DHA:ASIATICLAB
32 GF Score
Price BDT142.20
! 1 Warning Sign
View Full Analysis

What is Asiatic Laboratories Debt-to-EBITDA?

Asiatic Laboratories DHA:ASIATICLAB -0.56% 32 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates DHA:ASIATICLAB with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 690 Drug Manufacturers companies, Asiatic Laboratories ranks worse than 144927.39% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Asiatic Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in . 20 was BDT0.00 Mil. Asiatic Laboratories's annualized EBITDA for the quarter that ended in . 20 was BDT0.00 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Asiatic Laboratories's Debt-to-EBITDA or its related term are showing as below:

DHA:ASIATICLAB's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.67
* Ranked among companies with meaningful Debt-to-EBITDA only.

Asiatic Laboratories  (DHA:ASIATICLAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Asiatic Laboratories Debt-to-EBITDA Related Terms

Asiatic Laboratories Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Asiatic Laboratories's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Asiatic Laboratories Debt-to-EBITDA Chart

Asiatic Laboratories Annual Data
Trend
Debt-to-EBITDA

Asiatic Laboratories Semi-Annual Data
Debt-to-EBITDA

DHA:ASIATICLAB vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Asiatic Laboratories's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asiatic Laboratories Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Asiatic Laboratories's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Asiatic Laboratories's Debt-to-EBITDA falls into.


DHA:ASIATICLAB
32GF Score
Asiatic Laboratories Ltd DHA:ASIATICLAB
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Asiatic Laboratories Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Asiatic Laboratories's Debt-to-EBITDA for the fiscal year that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / N/A
=N/A

Asiatic Laboratories's annualized Debt-to-EBITDA for the quarter that ended in . 20 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + ) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (. 20) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Asiatic Laboratories (DHA:ASIATICLAB) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asiatic Laboratories. According to the industry distribution chart, Asiatic Laboratories ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Asiatic Laboratories' Debt-to-EBITDA too high?
Asiatic Laboratories' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Asiatic Laboratories ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Asiatic Laboratories has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Asiatic Laboratories' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Asiatic Laboratories ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Asiatic Laboratories in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Asiatic Laboratories. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asiatic Laboratories's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asiatic Laboratories stock overvalued right now?
Asiatic Laboratories (DHA:ASIATICLAB) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Asiatic Laboratories' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Asiatic Laboratories (DHA:ASIATICLAB), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Asiatic Laboratories Business Description

Address Siddeshwari Circular Road, 42-43, Treasure Island (5 th Floor) Shantinagar, Dhaka, BGD, 1217
Asiatic Laboratories Ltd is engaged in manufacturing and marketing of a wide range of the rapeutical medicines pharmaceutical products in the categories of Biological, Non-Biological & Sterile Pharmaceutical dosage. It has 80 generic molecules comprising therapeutic classes like antibiotics, antihistamines, bronchodilators, vitamins-minerals, antiulcerants, laxatives, gastroprokinetics, antihematinic, anthelmentics, CNS drugs, respiratory drugs, NSAIDs, dermatological preparations and sterile ophthalmic preparations.
32GF Score

Get the complete analysis for DHA:ASIATICLAB

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT142.20
Price